BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid …,

BT-001 is our fourth program in clinical development. We are very excited to move forward this unique oncolytic virus which combines multiple, clinically …, BT-001 is our fourth program in clinical development. We are very excited to move forward this unique oncolytic virus which combines multiple, clinically …, Read More

Scroll to Top